Data compiled by Redley Lamar · ChainSifter Intelligence
7Suppliers
5Customers
1Debt Items
20Related Chains
Source-Backed Evidence Depth
Silence Therapeutics plc (SLN) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.
13Total relationships
3Distinct source URLs
7High confidence
0.788Average confidence
2026-10-28Latest database update
ChainSifter does not infer unreported suppliers, customers, ownership, acquisitions, debt exposure, revenue dependency, or future supply-chain events on this public page.
Reciprocal relationship from AZN graph: Reciprocal relationship from SLN graph: Reciprocal relationship from AZN graph: Reciprocal relationship from SLN graph: Under this agreement, AstraZeneca made …
HANSOH-PHARMACEUTICAL-GROUP-COMPANY-LIMITED
HANSOH-PHARMACEUTICAL-GROUP-COMPANY-LIMITED
90%
In the past, we have entered into collaborations with other parties, including pharmaceutical and biotechnology companies like Hansoh Pharmaceutical Group Company Limited, or Hansoh, and AstraZeneca …
JEFFERIES-LLC
JEFFERIES-LLC
90%
Under the Sales Agreement, the Company may offer and sell, from time to time, through Jefferies as its sales agent and/or principal, American Depositary Shares of the Company
MALLINCKRODT-PLC
MALLINCKRODT-PLC
80%
In March 2024, Mallinckrodt notified us that they will not pursue further development of SLN501
Reciprocal relationship from ALNY graph: ts or insider trading violations, which could significantly harm our business, prospects, operating results and financial condition. We are exposed to the ris…
Reciprocal relationship from BDRX graph: ive award is recognized as an expense over the requisite service period of the award, which is usually the vesting period. Compensation expense is recognized …
Reciprocal relationship from AZN graph: Reciprocal relationship from SLN graph: Reciprocal relationship from AZN graph: Reciprocal relationship from SLN graph: Reciprocal relationship from AZN graph:…
the Group’s operating leases at December 31, 2024: Fiscal year Operating Leases 2025 117 2026 - 2027 - 2028 - 2029 - Thereafter - Total expected lease payments 117 Less: Imputed interest - Total leas…
ALL-WALES-MEDICINES-STRATEGY-GROUP
ALL-WALES-MEDICINES-STRATEGY-GROUP
62%
2030. Selected high-risk medical devices will also be assessed under the HTA Regulation as of 2026. The HTA Regulation is intended to harmonize the clinical benefit assessment of HTA across the EU an…
COORDINATION-GROUP
COORDINATION-GROUP
62%
ices resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the federal civil False Claims Act or the civil monetary penalties statute…
LEASES-THE-GROUP
LEASES-THE-GROUP
62%
onsideration it is entitled to in exchange for the goods or services it transfers to the customer. As part of the accounting for these arrangements, the Group must make significant judgments, includi…
Silence Therapeutics plc Debt Obligations
Instrument
Description
Confidence
Evidence
SLN-DEBT
Debt stack $136,000
90%
Market cache reports total debt of $136,000.
Silence Therapeutics plc Acquisitions
No acquisitions on recordNo completed or pending acquisitions found in our database for Silence Therapeutics plc.
Silence Therapeutics plc Ownership
No ownership data on recordNo major institutional ownership relationships found in our database for Silence Therapeutics plc.
